Patents Assigned to Ionis Pharmaceuticals, Inc.
-
Patent number: 12152052Abstract: Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of methyl CpG binding protein 2 (MECP2) RNA in a cell or animal, and in certain instances reducing the amount of MECP2 protein in a cell or animal Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include MECP2 duplication syndrome. Such symptoms or hallmarks include autism, intellectual disability, motor dysfunction, hypotonia, global developmental delays, gastrointestinal symptoms, anxiety, epilepsy, recurrent respiratory tract infections, epileptic encephalopathy, and early death.Type: GrantFiled: September 22, 2023Date of Patent: November 26, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventor: Susan M. Freier
-
Patent number: 12152244Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.Type: GrantFiled: January 27, 2022Date of Patent: November 26, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
-
Publication number: 20240382605Abstract: Provided herein are oligomeric compounds comprising a bicycle ligand and a modified oligonucleotide. This compound may comprise a bicycle ligand as the cell-targeting moiety, and may also comprise a conjugate linker to connect the bicycle ligand and modified oligonucleotide. This compound may be used in conjunction with a pharmaceutically acceptable salt.Type: ApplicationFiled: September 29, 2022Publication date: November 21, 2024Applicants: Ionis Pharmaceuticals, Inc., BicycleTx LimitedInventors: Punit P. Seth, Michael Oestergaard, Michele Carrer, Michael Tanowitz, Michael Rigby, Michael Skynner, Steven Stanway, Liudvikas Urbonas, Katerine Van Rietschoten
-
Publication number: 20240376469Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of HTT RNA in a cell or subject, and in certain instances reducing the amount of HTT protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom or hallmark of a repeat expansion disease. Such repeat expansion diseases include myotonic dystrophy, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, polyglutamine disorders, Fragile X syndrome, and spinocerebellar ataxia. Such symptoms or hallmarks include brain atrophy, muscle atrophy, nerve degeneration, uncontrolled movement, seizure, tremor, anxiety, and depression.Type: ApplicationFiled: January 28, 2022Publication date: November 14, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Bethany Fitzsimmons, Susan M. Freier, Holly Kordasiewicz
-
Publication number: 20240368592Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: December 5, 2023Publication date: November 7, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
-
Publication number: 20240360448Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified intemucleoside linkage. In some embodiments, the disclosure provides oligomeric compounds and modified oligonucleotides comprising a central region in which purine-containing central region nucleosides are adjacent to methanesulfonyl phosphoramidate intemucleoside linkages.Type: ApplicationFiled: August 17, 2022Publication date: October 31, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Hans-Joachim Josef Gaus, Punit P. Seth
-
Publication number: 20240360449Abstract: Provided are oligomeric compounds, methods, and pharmaceutical compositions for modulating expression of SCN1A RNA and/or protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a developmental or epileptic encephalopathic disease, such as, for example, Dravet Syndrome. Such symptoms include seizures, sudden unexpected death in epilepsy, status epilepticus, behavioral dysfunctions, movement and balance dysfunctions, orthopedic conditions, motor dysfunctions, cognitive impairment, delayed language and speech, visual motor integration dysfunctions, visual perception dysfunctions, executive dysfunctions, and dysautonomia.Type: ApplicationFiled: August 26, 2022Publication date: October 31, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Paymaan Jafar-nejad, Frank Rigo
-
Publication number: 20240360453Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in a cell or animal, and in certain instances reducing the amount of LRRK2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include Parkinson's disease.Type: ApplicationFiled: November 29, 2023Publication date: October 31, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Tracy A. Cole, Holly Kordasiewicz, Huynh-Hoa Bui, Susan M. Freier
-
Patent number: 12129466Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurogenetic disorder. Such symptoms and hallmarks include developmental delays, ataxia, speech impairment, sleep problems, seizures, and EEG abnormalities. Such neurogenetic disorders include Angelman Syndrome.Type: GrantFiled: January 14, 2022Date of Patent: October 29, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventor: Paymaan Jafar-nejad
-
Patent number: 12115225Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.Type: GrantFiled: April 15, 2021Date of Patent: October 15, 2024Assignees: ASTRAZENECA AB, IONIS PHARMACEUTICALS, INC.Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. Kinberger, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury, III
-
Publication number: 20240335556Abstract: Provided are oligomeric compounds, methods, and pharmaceutical compositions for DMPK the amount or activity of DMPK RNA in a cell or animal, and in certain instances reducing the amount of DMPK protein in a cell or animal. Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat type 1 myotonic dystrophy.Type: ApplicationFiled: October 13, 2023Publication date: October 10, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Frank Rigo, Chrissa A. Dwyer
-
Publication number: 20240336915Abstract: Provided are compounds, pharmaceutical compositions, and methods of use for reducing the amount or activity of DUX4 RNA in a cell or animal, and in certain instances reducing the amount of DUX4 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a muscular dystrophy. Such symptoms and hallmarks include muscle weakness and/or muscle wasting in facio, scapula, and/or humeral muscle that can progress to the muscles of the trunk and/or lower limbs. Such muscular dystrophies include Facioscapulohumeral muscular dystrophy (FSHD).Type: ApplicationFiled: January 21, 2022Publication date: October 10, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Ruben E. Valas, Paymaan Jafar-nejad, Frank Rigo, Susan M. Freier, Huynh-Hoa Bui, Priyam Singh
-
Patent number: 12110491Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).Type: GrantFiled: January 18, 2022Date of Patent: October 8, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
-
Publication number: 20240325425Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use for selectively reducing the amount or activity of HTT RNA comprising SNP rs7685686 in a cell or subject, and in certain instances reducing the amount of mutant HTT protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of Huntington's disease.Type: ApplicationFiled: February 16, 2024Publication date: October 3, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Punit P. Seth
-
Publication number: 20240318183Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.Type: ApplicationFiled: October 18, 2023Publication date: September 26, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Huynh-Hoa Bui
-
Publication number: 20240316092Abstract: Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).Type: ApplicationFiled: October 24, 2023Publication date: September 26, 2024Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute For Cancer ResearchInventors: Huynh-Hoa Bui, Don W. Cleveland, Ze'ev Melamed
-
Publication number: 20240309452Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).Type: ApplicationFiled: October 16, 2023Publication date: September 19, 2024Applicants: Ionis Pharmaceuticals, Inc., The University of British ColumbiaInventors: C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
-
Publication number: 20240309374Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.Type: ApplicationFiled: October 24, 2023Publication date: September 19, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Gene Hung, C. Frank Bennett
-
Publication number: 20240301415Abstract: Provided are oligomeric compounds and pharmaceutical compositions for increasing the amount or activity of UNC13A RNA in a cell or animal, and/or decreasing the amount of UNC13A RNA that includes a cryptic exon in a cell or animal, and in certain instances increasing the amount of UNC13A protein in a cell or animal. Such oligomeric compounds and pharmaceutical compositions are useful to treat neurodegenerative diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.Type: ApplicationFiled: May 20, 2022Publication date: September 12, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Ruben E. Valas, Kar Yun Karen Ling
-
Publication number: 20240301412Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation formation, and neuron death. Such neurodegenerative diseases include spinocerebellar ataxia type 3(SCA3).Type: ApplicationFiled: October 12, 2023Publication date: September 12, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventor: Susan M. Freier